Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx xxxx a xxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx věcí x. 58/2007 Sb. x. x. x č. 46/2008 Sb. m. x.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že xxx 1. xxxxx 2017 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx dopingu xxx xxx 2018 - Xxxxxxxxxxx xxxxxxxx Mezinárodní xxxxxx proti xxxxxxx xx sportu¹⁾.

S xxxxx xxxxxx Xxxxxxx X xxxxxxxx souhlas Parlament Xxxxx xxxxxxxxx a xxxxxxxxx republiky xxxxxxxx xxxxxxx o xxxxxxx xxxx Přílohy X Xxxxxx republikou.

Nové xxxxx Xxxxxxx I xxxxxxxxx x platnost v xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2018. Xxx Xxxxxx xxxxxxxxx xxxxxxxxx xxxx xxxxx Xxxxxxx X x xxxxxxxx xxx 5. xxxxxx 2019.

Xxxx xxxxxx xxxxxx znění Xxxxxxx X v xxxxxxxx přestalo xxxxxx xxxxx Přílohy X xxxxxx xx 1. xxxxx 2017 a xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Xxxxxxxx xxxxx xxxxxx znění Xxxxxxx I x xxxx xxxxxxx xx xxxxxxx xxxxxx se xxxxxxxxx xxxxxxxx.

XXXXXXX

XXXXXXXXXXXXX

XXXXXXXX

XXXXXXX XXXXXXXXXXXXX XXXXX

XXXXXX XXXXXXXXXX XXXXX X METOD DOPINGU XXX ROK 2018

MEZINÁRODNÍ XXXXXXXX

Xxxxxxxxx text Xxxxxxx xxxx xxxxxxxxx XXXX x bude publikován x xxxxxxxxxx x xxxxxxxxxxxxx.

X xxxxxxx xxxxxxxxxxx xxxxxxxxx mezi xxxxxxxxx x francouzskou verzí xxxx xxxxxxxxxxx anglická xxxxx.

Xxxxx Xxxxxx bude xxxxxx od 1. xxxxx 2018 

XXXXXX XXXXXXXXXX XXXXX A METOD XXXXXXX XXX XXX 2018

XXXXXXX ANTIDOPINGOVÝ XXXXX

Xxxxxx xx 1. xxxxx 2018

XXXXX X XXXXXX XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx xxxxx budou xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx S1, X2, X4.4, X4.5 x X6(x) a Xxxxxxxxxx xxxxx X1, X2 a X3.

XXXXXXXX XXXXX

X0. XXXXXXXXXXX LÁTKY

Jakákoliv xxxxxxxxxxxxx látka, která xxxx zahrnuta v xxxxxxxxxxxxx xxxxxxx Xxxxxxx x není aktuálně xxxxxxxxx pro xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx nebo xxxxxxxxx stadiu xxxxxxx xxxx po xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx veterinární xxxxxxx), xx zakázána xxxxx.

X1. XXXXXXXXXX LÁTKY

Anabolické látky xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):

(x) Xxxxxxxx* XXX, zahrnující:

1-androstendiol (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-dihydroxyandrost-4-en-3-on);

kalusteron;

klostebol;

mestanolon;

mesterolon;

metandienon (17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9-dien-3-on);

methyl-1-testosteron (17ß-hydroxy-17α-methyl-5α-androst-1-en-3-on);

methylnortestosteron (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-hydroxy-17α-methylestra-4,9,11-trien-3-on);

miboleron;

norboleton;

norethandrolon;

norklostebol;

oxabolon;

oxandrolon;

oxymesteron;

oxymetolon;

prostanozol (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-hydroxy-18α-homo-19-nor-17α-pregna-4,9,11-trien-3-on);

trenbolon (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

x. Endogenní** XXX, pokud xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol);

androstendion (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx metabolity x xxxxxxx, xxxxxx, xxx xx s omezením xxxxx xx ně:

5α-androstan-3α,17α-diol;

5α-androstan-3α,17ß-diol;

5α-androstan-3ß,17α-diol;

5α-androstan-3ß,17ß-diol;

5ß-androstan-3α,17ß-diol;

5α-androst-2-en-17-on;

androst-4-en-3α,17α-diol;

androst-4-en-3α,17ß-diol;

androst-4-en-3ß,17α-diol;

androst-5-en-3α,17α-diol;

androst-5-en-3α,17ß-diol;

androst-5-en-3ß,17α-diol;

4-androstendiol (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Ostatní xxxxxxxxxx xxxxx, zahrnující:

Klenbuterol; xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM, xxxx. xxxxxxx, LGD-4033, xxxxxxx x RAD140); xxxxxxx; xxxxxxx x zilpaterol, xxx ne x xxxxxxxx xxxxx xx xx.

Xxx xxxxx xxxxxxx xxxx sekce: * "exogenní" xx vztahuje k xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx. ** "xxxxxxxxx " se xxxxxxxx x xxxxx, xxxxxx xxxx normálně xxxxxxxxx produkuje.

S2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

Xxxxxxxxxxx látky x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx zakázány:

1. Xxxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx, xxxxxx, ale ne x omezením pouze xx ně:

1.1 Agonisté xxxxxxxxxxxxxxxxx xxxxxxxxx, např

darbepoetiny (xXXX); erytropoetiny (EPO); xxxxxxxxxx xxxxxxxx na XXX (XXX-Xx, methoxypolyethylenglykol-epoetin xxxx (CERA)); EPO-mimetické xxxxxxxxxx x xxxxxx xxxxxxxxxx (např. CNTO 530 x xxxxxxxxxxx).

1.2 Xxxxxxxxx prostředky xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (XX-4592); xxxxx.

1.3 Xxxxxxxxxx XXXX, xxxx.

X-11706.

1.4 Xxxxxxxxxx XXX - xxxx (XXX - β), xxxx.

xxxxxxxxxxxx; xxxxxxxxxxx.

1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx. např.

asialo EPO; xxxxxxxxxxxxx EPO.

2. Xxxxxxxxx xxxxxxx a hormonové xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (XX) x xxxxxxxxxxxx xxxxxx (XX) x jejich xxxxxxxxxx faktory, xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x triptorelin, u xxxx.

2.2 Xxxxxxxxxxxxxx x xxxxxx uvolňující xxxxxxx, xxxx. kortikorelin.

2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxxxx a xxxxxxxxxx xxxxxxx, včetně, xxx xx x omezením xxxxx na xx:

xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. XXX-9604 a xXX 176-191; hormon xxxxxxxxxx xxxxxxx xxxxxx (XXXX) x jeho analoga, xxxx. XXX-1295, xxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX), xxxx. ghrelin x xxxxxxxx xxxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxx peptidy xxxxxxxxx xxxxxxx (GHRP), xxxx. alexamorelin, GHRP-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, XXXX-5, XXXX-6 x xxxxxxxxx.

3. Xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx, včetně, xxx ne x xxxxxxxx pouze xx xx:

xxxxxxxxxxxxx xxxxxxx faktory (XXXx);

xxxxxxxxxxxx xxxxxxx xxxxxx (XXX);

xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (XXX-1) x xxxx analoga

mechanické růstové xxxxxxx (XXX);

xxxxxxx xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX);

xxxxxxxx- β4 x jeho deriváty, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (VEGF).

Další růstové xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx ovlivňující xxxxxxx nebo xxxxxxxxx xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, využití energie, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.

X3. BETA2- XXXXXXXX

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 xxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx xxxxxxxx.

Xxxxxxxx (xxx xx s xxxxxxxx xxxxx xx ně):

Fenoterol; xxxxxxxxxx; xxxxxxxxx; indakaterol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; salmeterol; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: maximálně 1600 xxxxxxxxxx xx 24 xxxxx v oddělených xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx xxxxx xxxxxxx 12 xxxxx po xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx vyšší xxx 1000 xx/xx x přítomnost xxxxxxxxxxx x xxxx v xxxxxxxxxxx xxxxx než 40 xx/xx nebude xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx nález, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx výsledek xxx způsoben xxxxxxxxxxxxx xxxxxx (x xxxxxxxx) xxxxx, než výše xxxxxxx xxxxxxxxx xxxxx.

X4. XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx xxxxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (androstatriendion);

androsta-3,5-dien-7-17-dion (arimistan);

4-androsten-3,6,17-trion (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, xxx xx x omezením xxxxx xx xx.

2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx receptorů (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx, xxx xx x omezením xxxxx na xx.

4. Xxxxx modifikující xxxxxx(x) xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.

5. Metaboiické xxxxxxxxxx:

5.1 Aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX; a Agonisté Xxxxxxxxx xxxxx xxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) kyselina xxxxxx (GW1516, XX501516);

5.2 xxxxxxxx a xxxxxxxx xxxxxxxx;

5.3 meldonium;

5.4 trimetazidin.

S5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx diuretika x xxxxxxxxx látky jsou xxxxxxxx, stejně jako xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx x podobnými xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; xxxxxxxxxxxxxxx (např. xxxxxxxxxx xxxxxx albuminu, xxxxxxxx, hydroxyethylškrobu x xxxxxxxxx); probenecid, ale xx x xxxxxxxx xxxxx xx xx.

• Xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxx; xxxxxxxxx; kanrenon; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; thiazidy (např. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx); xxxxxxxxxx a vaptany (xxxx. xxxxxxxxx), ale xx x xxxxxxxx xxxxx xx ně.

S xxxxxxxx:

• xxxxxxxxxxxx; pamabromu x xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxxx x xxxxxxxxxxxx)

• Xxxxxxxxx podání xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx jakéhokoliv množství xxxxx xx stanoveným xxxxxxxx xxxxxxx (tj. xxxxxxxxxx, xxxxxxxxxx, katin, xxxxxxx, metylefedrin x xxxxxxxxxxxxx) ve Vzorku Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Při Xxxxxxx xx xxxxxxx s xxxxxxxxxx xxxx jinou xxxxxxxxx látkou, xxxx xxxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx nemá xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (TV) xx xxxx xxxxx xxxxx x té, xxxxx xxx byla xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. XXXXXXXXXX X KRVÍ X XXXXXXXX KOMPONENTAMI

Zakázané xx xxxxxxxxxxx:

1. Podání xxxx xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, alogenní (xxxxxxxxx) xxxx heterologní xxxx xxxx červených xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx oběhového systému.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx xxxxxxxx xxxxxxxx xx hemoglobinu x xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx a xxxxxxxxxxx (XXX13), xxx xx x omezením xxxxx xx ně. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx s xxxx xxxx x xxxxxxxx komponentami fyzikálními xxxx chemickými xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Xxxxx x Xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Vzorků xxxxxxxxxx při Xxxxxxxxx xxxxxxxx. Xx zahrnuje xxxxxx a/nebo úpravu (xxxx. proteázami) xxxx, xxx xx x xxxxxxxx pouze xx xx.

2. Xxxxxxxxxx infuze x/xxxx injekce xxxx xxx celkem 100 xx za 12 xxxxx kromě xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx zákroků, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X3. XXXXXX DOPING

Z důvodu xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx následující:

1. Xxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx jejich analogů;

2. Xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxx x/xxxx x xxxxxxxxxxxx xxxx xxxxxxxxxxxx xxxxxxxx xxxxxx xxxxxxx.

3. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX X XXXXXX ZAKÁZANÉ PŘI XXXXXXX

Xxxxx kategorií S0 xx X5 x X1 xx X3 xxxxxxxxx xxxx

xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx skupiny:

ZAKÁZANÉ LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx stimulancia xxxxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, např. x- x X-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-fenylpiracetam (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x tomto xxxxxxxx, xx Specifickou xxxxxx.

(x) Xxxxxxxxxx stimulancia.

Zahrnují (xxx xx x xxxxxxxx xxxxx na ně):

Adrenalin (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx a xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxx;

xxxxx**;

xxxxxxx x xxxx xxxxxxx (xxxx. xxxxxxxx, xxxxxxxxx a xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx/xxxxxx použití x stimulancií xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx rok 2018*.

* Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, pipradrol x xxxxxxxx: Xxxx xxxxx jsou zahrnuté xx Monitorovacího xxxxxxxx 2018 a xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx: xx xxxxxxxx pouze při xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.

*** Xxxxxxx a xxxxxxxxxxxxx: xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx xxxx.

**** Xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxx xxx lokálním xxxxxx, xxxx. xxxxx, xxxx xxxxxxxx xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

***** Xxxxxxxxxxxxx: je xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx xx xxxxx než 150 xxxxxxxxxx xx mililitr.

S7. XXXXXXXXX

Xxxxxxxxxxx narkotika jsou xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. KANABINOIDY

Následující kanabinoidy xxxx zakázané:

• Přírodní xxxxxxxxxxx, xxxx. xxxxx, xxxxxx x xxxxxxxxx.

• Xxxxxxxxxx kanabinoidy, xxxx. delta9-tetrahydrokanabinol (XXX) x ostatní kanabimimetika.

Kromě: xxxxxxxxxxxx

X9. GLUKOKORTIKOIDY

Všechny xxxxxxxxxxxxxxx xxxxxxxx xxxxxx, rektálně, xxxxxxxxxx xxxx nitrosvalovou xxxxxxxx jsou xxxxxxxx.

Xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX ZAKÁZANÉ V URČITÝCH XXXXXXXX

X1. BETA-BLOKÁTORY

Beta-blokátory jsou xxxxxxxx xxxxx x xxxxxxxxxxxxx sportech Xxx Xxxxxxx, x kde xx xx xxxxxxxx x Xxxx xxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (xxxxxxx xxxxxxxxxx) (WCBS)

• Golf (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (XXX) - xxxxx xx lyžích x xxxxxxxxxxx lyžování-skoky x X-xxxxx, x xxxxxxxxx U-rampa x "xxx xxx"

• Xxxxxxxx xxxxxx (xxxxxxxxx xxxxxxxx) (CMAS) x xxxxxxxxxxxx xxxxxxxxxx xxxx x ploutvemi xxxx bez ploutví, xxxxxxxxx apnoe x xxxxxxxxx xxxx xxx xxxxxxx, xxxx immersion, xxxx xxxx, xxxxxxxxxxxx, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx xx xxxx x variabilní xxxx.

• Xxxxxxx (XXXX, XXX)*

• Xxxxx (XXX)

* Xxxxxxxx také Mimo xxxxxx

Xxxx-xxxxxxxxx zahrnují následující xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx ne x xxxxxxxx xxxxx xx xx.

Informace

Právní xxxxxxx č. 36/2019 Xx. x. x. nabyl xxxxxxxxx xxxx 26.7.2019.

Právní xxxxxxx x. 36/2019 Xx. x. s. xxx xxxxxx právním xxxxxxxxx č. 32/2023 Sb. m. s. s xxxxxxxxx xx 22.8.2023.

Xxxxx jednotlivých xxxxxxxx norem jiných xxxxxxxx xxxxxxxx x xxxxxxxx není aktualizováno, xxxxx se xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Mezinárodní xxxxxx xxxxx xxxxxxx ve xxxxxx, xxxxxxx xxx 19. října 2005 x Xxxxxx, byla xxxxxxxxx x xxxxxxxxx xxxxx a s xxxxxxxxx do xxxxxxx xxxxxx xxx č. 58/2007 Sb. m. s.

Xxxx xxxxx xxxxxxxx Xxxxxx xx xxxxxxx xxxxxx xxxx xxxxxxxxx pod č. 46/2008 Sb. m. s.